INTRODUCTION
The evaluation of the potential carcinogenicity of lead and lead compounds on the basis of epidemiologic and experimental data for human health risk assessment does not allow clearcut conclusions. The EPA proposed classification of lead and lead compounds as probable (B2) human carcinogens, while I ARC defined lead and lead inorganic compounds as 2B carcinogens, (inadequate evidence in humans and sufficient evidence in animals).
Recent epidemiologic studies do not confirm experimental results showing that lead induces kidney cancer. However, a statistically significant increased lung cancer mortality was observed in human groups occupationally exposed to lead in battery manufacturing and smelting industries (Cooper and Gaffey, 1975; Cooper etal., 1985) .
A co-carcinogenic effect of lead oxide with benzo-a-pyrene was found by Kobayashi et al. (1974) after intratracheal instillation in hamsters, for relatively low lead lung burden (9 mg). However, animal experimental data on pulmonary carcinogenesis using the inhalation route are lacking.
The aim of this work was to ascertain whether lead oxide acts as a complete lung carcinogen when inhaled alone, or as a lung co-carcinogen in rats previously exposed to fission neutrons, irradiation acting then as an initiator; or a lung co-carcinogen in rats exposed first to lead oxide by inhalation and by the end of the inhalation period to intramuscular injections of 5-6 benzoflavone (|3NF), which has been previously demonstrated to be a specific promotor of experimentally induced squamous cell lung carcinoma in Sprague-Dawley rats (Morin et al., 1978) .
MATERIAL AND METHODS
The most important limitation to ascertain lead pulmonary induced carcinogenesis after inhalation is the occurrence of kidney cancers in rats at cumulative doses higher than 2 g, as found by Azar et al. (1973) . Thus, the exposure level in the inhalation chambers for the long-term inhalation carcinogenesis study had to be adjusted so that the cumulative lead kidney burden resulting from a 1 year inhalation exposure to lead oxide would be equivalent to that achieved after a 2 years exposure to 500 ppm of lead acetate in the diet. This dose is the lowest one Inhaled lead oxide particles in rats 631 which has been shown to be associated with lead, or lead compounds, induced kidney tumours. Accordingly, a "pilot experiment" was primarily carried out to determine the toxicokinetics of lead oxide inhaled by whole body inhalation exposure in rats, compared with those of lead oxide and lead acetate given by ingestion route (gavage). It allowed us to determine that the inhalation exposure of rats at 5 mg m~3, 6 h a day, 5 days a week, during one year should be grossly equivalent to a cumulative dose of lead acetate (about 3-4 g) given by gavage. Such a dose is about two-fold lower than that inducing 10% of kidney cancers in the experiment of Azar et al. (1973) .
The long-term inhalation carcinogenesis study was carried out on four experimental groups of Sprague-Dawley male rats.
• Group 1: 63 rats exposed to 0.6 Gy fission neutrons. In our series, this dose has been shown to result in a 10% incidence of lung cancers and a 3% incidence of kidney cancers (Morin and Lafuma, 1990 ).
• Group 2: 50 rats exposed to 0.6 Gy fission neutrons and 2 months later, exposure to lead oxide by inhalation for 1 year as previously determined.
• Group 3: 50 rats exposed to lead oxide alone by inhalation for 1 year.
• Group 4: 25 rats exposed to lead oxide by inhalation for 1 year and 1 month after the end of exposure treated with six intramuscular injections of |5NF.
Irradiation
The rats were exposed to fission neutrons in the "Silene" experimental reactor facilities according to the pulse operating mode with a 10 cm thick lead shielding. The rats were placed into individual aluminium containers suspended on a net 4 m distant from the core of the reactor.
The number of fissions was: 4.88 10
16
. The peak power was: 1.23 10 17 fissions s"
1 . The dose was: 0.62 Gy neutrons and 0.135 Gy gamma rays.
Lead inhalation exposure
The whole body inhalation exposure was performed into a 2 m 3 dynamic type Hazleton exposure chamber. The rats were housed continuously in individual wire cages in the chambers throughout the inhalation period, provided tap water ad libitum and fed outside of exposure hours. The aerosolization of dry dust lead oxide was achieved by means of a TSI Model 3433 Small-Scale Powder Disperser. The generator was calibrated so that the concentration of lead oxide aerosol into the chamber be 5 mg m~3. The airborne concentration of lead oxide particles into the chamber was controlled gravimetrically using HAWP 047 0M previously weighed Millipore filters. At least three measurements were performed daily for each inhalation session. The mean lead oxide airborne concentration measured within the inhalation chamber during the 240 inhalation sessions performed was: 5.3 ±1.7 mg m~3. The aerodynamic size measurement of aerosolized particles was determined using an Andersen 1 ACFM Non-Viable Ambient Particle Sizing Sampler (Cascade Impactor). The equivalent aerodynamic diameters of lead oxide particles aerosolized into exposure chambers are listed in Table 1 . These results show that the fraction respirable by rats represented more than 60% of the total mass.
The actual diameter of aerosolized particles was determined on 50 1. aliquot air samples taken from the exposure chamber and collected on 0.2 jim pore size G. Monchaux et al. Millipore filters. The actual diameter of particles was determined by light microscopy using a Carl Zeiss Photomicroscope coupled with a video computerized image analysis system. The mean particle diameter was 0.69 urn (ag = 1.74).
Since the density of lead oxide particles is 9.5, the results obtained using the two different methods are in good agreement, the theoretical value of MM AD being 5.1 um compared with 4.7 urn < MM AD < 5.8 urn ( Table 1) .
Injection of the promotor (fiNF)
In the group treated with (3NF, 1 month after the end of the inhalation exposure, the rats received six intramuscular injections of 25 mg kg" 1 of (3NF at fortnightly intervals.
Animal and histologic analysis
The experiments were carried out on 10-week-old male SPF outbred OFA Sprague-Dawley rats. After their arrival in the laboratory, the animals were kept in quarantine for 1 week before any treatment and acclimated to inhalation exposure chambers for 1 week before the beginning of inhalation exposure. The rats were exposed as described above.
After exposure all rats were housed throughout their life-span in the same animal house, maintained on a 12 h light cycle. All animals were kept until moribund except those of the |3NF group (Group 4) which were killed 100 days after the last injection of |3NF. A full necropsy was performed in every animal. Liver, spleen, kidney, lungs and brain and all organs exhibiting macroscopic lesions were taken systematically. Histologic samples were fixed with Bouin-Hollande fixative solution. The entire lungs were fixed by intratracheal instillation of the fixative solution. Tissue samples were prepared in the form of 5 [Am paraffin sections stained with haematoxylin-eosin-saffron for histopathological examination.
Survival times
Tumour incidence and survival time were compared with those observed in a group of 785 untreated control rats, housed simultaneously in the same animal house and with those observed in three historical groups of rats exposed to fission neutrons in the Silene reactor (Morin and Lafuma, 1990) . 
RESULTS
Malignant tumours were differentiated into carcinomas and sarcomas. The proportion of cancers observed in the different organs of 785 control male rats and the proportion of cancers in the different organs of three historical groups of male rats exposed to a global irradiation by fission neutrons at different doses in the Silene reactor is indicated in Table 2 . In control male rats, the spontaneous incidence of kidney and lung carcinomas was very low, 0.64%. The global incidence of cancers, including both carcinomas and sarcomas was increased in all the groups exposed to fission neutrons but this increased incidence of cancers was higher in the group exposed to fission neutrons 1.15 Gy than in the other groups. In this group the incidence of lung carcinomas was multiplied by a factor of about 40 and the incidence of kidney carcinomas by a factor of about 20 compared with controls. The proportion of cancers in the different organs of male rats exposed either to irradiation by fission neutrons 0.6 Gy alone, or to lead oxide according to the different experimental schedules is indicated in Table 3 . The global incidence of cancers was lower in group 2 exposed to fission neutrons and lead oxide combined (34%) than in group 1 exposed to fission neutrons 0.6 Gy alone (47.9%).
The incidence of lung carcinomas was also lower in group 2 than in group 1. In G. 
this group, only one rat had two primitive lung carcinomas, a squamous cell carcinoma and a bronchioloalveolar adenocarcinoma, as compared with four lung carcinomas, two bronchogenic adenocarcinomas and two bronchioloalveolar carcinomas, observed in group 1. No significant survival time shortening was observed for the group exposed to lead oxide after previous irradiation by fission neutrons compared with that exposed to fission neutrons only, nor for the group exposed to lead oxide alone compared with untreated controls (Fisher's exact test).
DISCUSSION
These results did not show a direct carcinogenic effect of inhaled lead oxide in rats, nor did they show a co-carcinogenic effect of lead oxide under the experimental conditions used. In particular, the fact that no lung carcinomas were observed either after exposure to lead oxide alone, or after treatment by |3NF indicates that lead oxide is probably not a strong direct carcinogen and that it does not act as an initiator which could be revealed by PNF. They did not indicate either that lead oxide might act as a promoter after previous irradiation by fission neutrons. These results did not confirm the co-carcinogenic effect of lead oxide
